CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The company is Series A funded with US $ 7 million in funding so far
Data published in the prestigious journal ACS Central Science of the American Chemical Society
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Subscribe To Our Newsletter & Stay Updated
